Egfr Crosstalk
Egfr Crosstalk - Related Videos
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
08:32
Engineering Tendon Assembloids to Probe Cellular Crosstalk in Disease and Repair
0 Views •
Cited by 4 •
2024
Here, we present an assembloid model system to mimic tendon cellular crosstalk between the load-bearing tendon core tissue and an extrinsic compartment containing cell populations activated by disease and injury. As an important use case, we demonstrate how the system can be deployed to probe disease-relevant activation of extrinsic endothelial cells.
11:40
A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC
0 Views •
Cited by 7 •
2018
We present a protocol to investigate the crosstalk between X-ray-irradiated Caco-2 and peripheral blood mononuclear cells (PBMC). The protocol starts with Caco-2 irradiation and set-up of the co-culture with PBMC; subsequently, trans-epithelial electrical resistance is measured regularly over 48 h and western blot performed in both Caco-2 and PBMC.
08:52
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
0 Views •
Cited by 7 •
2021
This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid models.
FAQs
Ligand-driven EGFR phosphorylation initiates signaling through interconnected routes, including the RAS–RAF–MEK–ERK and PI3K–AKT networks. These pathways transmit the receptor’s activation state into intracellular programs that influence proliferation, survival, migration, and differentiation. Examining which downstream network is engaged helps explain how one receptor can produce different biological outcomes in distinct cellular contexts.
Other receptors can influence EGFR through transactivation, shared signaling effectors, or feedback loops. Transactivation allows one receptor system to modify EGFR activity, while shared effectors connect separate receptor inputs downstream. Feedback loops can further reinforce or adjust signaling. Together, these mechanisms let cells combine environmental cues rather than responding to EGFR activity in isolation.
Bidirectional communication means EGFR can affect other signaling systems while those systems also modify EGFR activity. This reciprocal exchange creates integrated responses instead of a simple one-way pathway. In biology, that integration helps coordinate whether cells proliferate, survive, migrate, or differentiate. The same connectivity can also make signaling behavior more adaptable when external conditions change.
Feedback loops provide a mechanism for signaling networks to reinforce or adjust EGFR activity after an initial stimulus. Because these loops connect receptor behavior with downstream pathways, they can shape how environmental information is integrated over time. In cancer research, identifying such regulation is relevant to understanding why pathway activity may persist or change when a treatment targets one signaling component.
Cancer research uses the crosstalk framework to examine how EGFR cooperates with other receptors and intracellular pathways. Investigators can focus on shared effectors, transactivation, feedback relationships, and downstream networks such as RAS–RAF–MEK–ERK or PI3K–AKT. This analysis helps connect signaling interactions with therapeutic resistance and with the search for cooperating pathways.
EGFR signaling is embedded in networks that include other receptors, shared effectors, and intracellular pathways. If cooperating routes continue to influence the same cellular programs, blocking EGFR may not fully suppress responses linked to proliferation or survival. Studying these connections therefore supports the rationale for considering combinations of targeted treatments rather than evaluating EGFR as an isolated control point.
Analysis of EGFR crosstalk can relate receptor interactions to changes in cell proliferation, survival, migration, and differentiation. In normal biology, this provides context for how cells coordinate multiple environmental cues. In cancer research, the same analysis can clarify therapeutic resistance, reveal cooperating signaling pathways, and help guide targeted treatment combinations aimed at interconnected rather than independent mechanisms.